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Abstract
Background: Here we describe PathogenMIPer, a software program for designing molecular
inversion probe (MIP) oligonucleotides for use in pathogen identification and detection. The
software designs unique and specific oligonucleotide probes targeting microbial or other genomes.
The tool tailors all probe sequence components (including target-specific sequences, barcode
sequences, universal primers and restriction sites) and combines these components into ready-to-
order probes for use in a MIP assay. The system can harness the genetic variability available in an
entire genome in designing specific probes for the detection of multiple co-infections in a single
tube using a MIP assay.
Results: PathogenMIPer can accept sequence data in FASTA file format, and other parameter
inputs from the user through a graphical user interface. It can design MIPs not only for pathogens,
but for any genome for use in parallel genomic analyses. The software was validated experimentally
by applying it to the detection of human papilloma virus (HPV) as a model system, which is
associated with various human malignancies including cervical and skin cancers. Initial tests of
laboratory samples using the MIPs developed by the PathogenMIPer to recognize 24 different types
of HPVs gave very promising results, detecting even a small viral load of single as well as multiple
infections (Akhras et al, personal communication).
Conclusion: PathogenMIPer is a software for designing molecular inversion probes for detection
of multiple target DNAs in a sample using MIP assays. It enables broader use of MIP technology in
the detection through genotyping of pathogens that are complex, difficult-to-amplify, or present in
multiple subtypes in a sample.
Background
Detection of the different types and subtypes of a patho-
gen is very important in clinical diagnosis. Over the past
several years, the development and application of molec-
ular diagnostic techniques has initiated a revolution in the
diagnosis and monitoring of infectious diseases. Advances
in molecular and cell biology have provided us with an
understanding of the mechanisms of disease at the molec-
ular level that can now be translated into designing new
diagnostic, prognostic, and therapeutic tools. It is now
Published: 14 November 2006
BMC Bioinformatics 2006, 7:500 doi:10.1186/1471-2105-7-500
Received: 26 June 2006
Accepted: 14 November 2006
This article is available from: http://www.biomedcentral.com/1471-2105/7/500
© 2006 Thiyagarajan et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Bioinformatics 2006, 7:500 http://www.biomedcentral.com/1471-2105/7/500
Page 2 of 10
(page number not for citation purposes)
possible to genotype/subtype pathogens to increase the
accuracy and reproducibility of diagnosis. Detection of
microbial DNA can provide not only a signature for the
presence of a disease, but may also indicate a drug-resist-
ant genotype, a particularly virulent subtype, a subtype
associated with other clinically important sequelae, or the
presence of multiple subtypes. These advances should
open the way for administering more effective and effi-
cient treatment for the control, prevention and cure of dis-
eases. There are several multiplex detection methods
currently in use, like DNA microarray, MUCH-AMASE,
multiple sequencing and pyrosequencing [1-5], but they
perform poorly in subtyping of pathogens in a sample, as
all of them needs a pre-amplification of DNA through a
PCR, and thus target a region of the whole genome where
PCR primers are possible. This limits the number of target
organisms or types/subtypes that can be detected in an
assay. Genomes of some viral pathogens are too diverse to
design a PCR primer pair whereas some pathogen
genomes have types and subtypes with less diversity for
designing specific probes.
Molecular Inversion Probe (MIP) technology was initially
developed for the detection of single nucleotide polymor-
phisms (SNPs) in human genes [6,18]. MIP technology
has been shown to work well for multiplexing, i.e. mas-
sive parallel processing (12,000 MIPs in the same reaction
tube) [7]. The power and versatility of MIP technology
makes it perfectly suited for the identification and quanti-
fication of microbes. MIP's high sensitivity and specificity
in detecting large numbers of SNPs [6,7] should allow one
to harness this technology to detect a large number of
pathogens and to identify multiple infections in an indi-
vidual sample. MIP assays are promising for a number of
clinical diagnostic applications such as detection of
microbial co-infections, antibiotic resistance and meas-
urements of microbial copy number in a single tube.
A molecular inversion probe is comprised of genomic rec-
ognition sequences, common amplification sequences
and a molecular barcode for each genotype assigned to a
specific gene. This probe is a linear oligonucleotide with
target-complementary sequences at the ends and a non-
complementary linking segment in between (Figure 1A).
Upon hybridization, the ends are brought together, creat-
ing a double helix with a gap of one or more nucleotides
such that polymerization to fill the gap and subsequent
ligation will occur only in the presence of a specific nucle-
otide. Upon appropriate filling and ligation, the oligonu-
cleotide is circularized and, due to the helical nature of
double-stranded DNA, it encircles the target DNA strand
(Figure 1B). Probes that are successfully filled and ligated
are amplified using universal primers (Figure 1C–E). A
universal barcode sequence allows for array detection and
quantification of amplified probe. This strategy provides
the following advantages: i) high level accuracy is reliably
obtained based on fidelity of both polymerase and ligase
in the gap-fill step, ii) high specificity is ensured from
hybridization, polymerization and ligation; indeed these
latter enzymatic reactions together result in very specific
and accurate pathogen typing. The use of a MIP in
genomic detection techniques is shown in figures 1A–1E.
In order to target the entire genome of a pathogen, the
probes must be very sensitive, and long enough to detect
even a few copies of the pathogen DNA in the sample. The
reliability of the MIP assay depends wholly on the specif-
icity and binding efficiency of the probes. To harness MIP
technology and make it available for widespread clinical
use, it will be necessary for researchers to rapidly design
high quality probes. The classical approach for designing
oligonucleotides, that is found in existing softwares [20-
24] were mainly developed for the design of microarray
probes, PCR or sequencing primers. Most of these soft-
ware tools use the same algorithms to design probes based
on the criteria specified by the user, and these approaches
are not always adapted to complex biological samples, for
which multiple organism detection is needed. The availa-
ble tools for MIP design [3,17] do not check for cross-
hybridization with the potential background, or host
genome. This is a critical factor in that cross-hybridization
could lead to misinterpretation of the results in a clinical
diagnosis. Here we describe PathogenMIPer, a tool for
designing unique and specific probes targeting microbial
(or other) genomes. In contrast to other MIP design pro-
grams, our system designs highly unique probes specific
for each target sequence through multiple, successive
steps of evaluation of candidates, followed by a final
check against non-target genomes potentially present in
the sample that could otherwise cause background noise
or interfere with signal. Because of its reliability and ease
of use, PathogenMIPer can be used by specialists and non-
specialists alike, which would allow MIP technology to
become more widely accessible.
Implementation
A molecular inversion probe (Figure 1A) consists of two
target specific binding segments, called homologue1 and
homologue2, that are homologous to the target sequence
and are separated by an optional single common middle
base nucleotide (A, G, T, or C) in the target. In a MIP, these
homologues are separated by two or more tag sequences,
which include a universal primer pair for the amplifica-
tion of all the target bound probes, and a unique tag
which detects and identifies each of the probes after bind-
ing to the target specifically. The MIP also may contain an
optional restriction or cleavage site. The total length of the
MIP will be around 100 bases, depending on the lengths
of target-binding homologues, primer sequence, restric-
tion site and unique tag.BMC Bioinformatics 2006, 7:500 http://www.biomedcentral.com/1471-2105/7/500
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The software first generates target sequences and then in
several consecutive steps eliminates unfit candidates. In
order to minimize the time required to perform a design
task, oligos are processed in several steps of increasing
computational intensity, with a recursive elimination of
unfit candidate probes at each of successive steps. The
processing steps in our MIP design are as follows:
1. Candidate probes for each of the target sequences are
generated with a userspecified binding length.
2. Candidates with a continuous stretch of six or more of
the same base are eliminated.
3. The middle base is checked for the preferred base
(A|G|T|C). Candidates without the preferred middle base
are eliminated.
4. The remaining candidates are checked against non-tar-
get genomes. If an absolute match is found, the candidate
is eliminated.
5. The middle 11-base region is checked against other
genomes to ensure uniqueness of probes and specificity of
the assay.
Automatically, the nonspecific candidates previously
identified for other targets are also removed.
Steps involved in a standard MIP Assay (Steps A – E) Figure 1
Steps involved in a standard MIP Assay (Steps A – E). H1 & H2 – Two segments homologous to the target genome, P1 
& P2 – Two universal primers common for all MIPs, R – Cleavage site. A) A Molecular inversion probe constructed using 
PathogenMIPer software, for each of the organism to be detected in the MIP assay. An oligo of user specified length is 
extracted from the target genome, and cut into two halves, reversed and tailored with the primer and other tags. B) Oligo 
hybridization with the samples. Done enzymatically – a mixture of the genomic DNA, MIP probes specific for all the targets, a 
thermostable polymerase and ligase, is heat denatured and brought to annealing temperature. i) Two sequences targeting each 
terminus of the probe hybridize to complementary sites in the genome creating a circular conformation with a single nucle-
otide gap between the termini of the probe. All the MIP probes are designed to have the same nucleotide at this position. ii) 
Unlabeled dATP/dGTP/dCTP/dTTP (any one selected by the user while designing the probe) is added to the reaction and the 
polymerase adds the nucleotide to the gap, and then iii) the ligase closes the gap to form a circular molecule that encircles the 
genomic strand, to which it's hybridized. C) Exonucleases are added to remove the excess unreacted linear probes and any lin-
ear genomic DNA. The reactions are then heated to inactivate the exonucleases. D) The probes are released from the 
genomic DNA by reacting with uracil-N-glycosylase. E) PCR reagents are added along with the common PCR primer pair. The 
reactions are subjected to thermal cycling, with the result that only circularized probes which bound to the specific target, are 
amplified. The probes are detected using a tag microarray or pyrosequencing.
TGTGCATAGAAAAGTTATACGCCGATGCGCATATTTACCAGGAGAAACTTATGGCTCAGGATATTCACACTAGAA
Target genome
ACGCCGATGCGCATATTTACCAGGAGAAACTTATGGCTCAG
P OH
5’
3’
H1 H2 P1 P2 Tag/barcode
Target binding sequence( 41mer) A) Molecular inversion probe
constructed
B) Oligo hybridization with the target genome
C) Exonuclease selection D) Probe release by cleavage
P1 P2 Tag/barcode H1 and H2
R
E) PCR followed by array hybridization or pyrosequencing
1. Annealing 2. Gap filling by polymerisation with single dNTP 3. Gap filling by ligation
ACGCCGATGCGCATATTTAC AGGAGAAACTTATGGCTCAG
H1 H2
Sequence of target binding part is 
cut into two halves and are reversed
CATTTATACGCGTAGCCGCA GACTCGGTATTCAAAGAGGA
5’ 3’
C CBMC Bioinformatics 2006, 7:500 http://www.biomedcentral.com/1471-2105/7/500
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6. Candidates are checked for their melting temperature
(Tm) and those that are beyond the desired range are
eliminated.
7. Candidate probes whose similarity to non-target
sequences exceeds a userspecified maximum are removed.
8. The remaining probes are screened against the potential
background caused by the host genome using an online
BLAST search [8] of the probes against the genome of the
host.
9. In the final step, the tags are added to complete the
design of ready-to-order probes. The tags are checked
against the binding segments of all probes, to make sure
that the addition of tags does not create a new recogniza-
ble sequence that may produce noise, false positives, or
background during target detection.
Initially (step 1), all sequences of the target with the spec-
ified binding length are considered as candidate probes.
Each target-specific sequence is first examined for the pres-
ence of poly As, Cs, Gs or Ts and candidates with more
than 6 repeats are eliminated (step 2). After completing
the check of the middle base (step 3) and an initial search
to eliminate homology with non-targets (step 4), the mid-
dle 11 base region of the probe, is checked against a non-
target sequence (step 5) and those with a continuous
stretch of similarity with the non-target sequences are
eliminated (step 6). In step 7, the candidates are checked
for their Tm using the nearest neighbor method [9-11].
Surviving candidates for each target are stored in a file for
later sorting and validation.
Each target sequence will have a pool of anywhere from
zero to a several thousands of probe candidates. The best
of the unique candidates are selected from each pool by a
selective filter tool (step 8). In step 8, each of the candi-
dates is scored for number of matching bases with the
non-target sequences using a BLAST search [8]. The scor-
ing is done in such a way that higher scores are given for
matches towards the middle region of the probe, where
the probe initiates binding with the target. When a candi-
date has a number of matching bases greater than the cut-
off value, that candidate is eliminated.
The design strategy used in our software evaluates specifi-
city at each step. Many existing oligo design tools [12-16]
are difficult to customize to attain the specificity required
for a molecular inversion probe. The application that
most closely addresses the needs of MIP design (Probe-
Maker) [11] falls short when the goal is to design unique
MIPs for distinguishing between 105 HPV types at the
same time. In general, there are many tools that are useful
for designing MIPs for the detection of SNPs [11], but they
fail when challenged to design MIPs for many subtypes of
a complex genome, such as MIPs to detect 105 HPV types
concurrently. Even if the number of tests or restrictions on
the probe candidates is reduced, these programs tend to
return a number of probes that is equal to the number of
all HPV types without any uniquely selective probes (in
the sense having more than 90% match in a non-target
HPV type). In addition to these problems, most of these
probes have close matches in the host genome, a property
that is critical to remove from a probe that will be used for
the detection of multiple subtypes of pathogens.
In order to design a sensitive, reliable and consistent MIP
assay, all probes for each target genome in the assay must
be very selective and the selectivity determinants should
be located mainly in the middle of the target binding
region. These criteria are not enforced in any of the exist-
ing tools. The problem is made more complicated in a real
biological situation, as some parts of the genome and of
the target(s) may be highly mutated, so that even probes
that are designed for a consensus target with high specifi-
city may fail to bind to the actual targets, because of natu-
ral variation. Thus a pathogen MIP design strategy should
include a user option to avoid particularly variable
regions of the genome during the design of target-specific
probes. The PathogenMIPer software allows for such
options.
PathogenMIPer designs candidate probes for each target
sequence through several computational steps as is shown
in Figure 2. The PathogenMIPer software accepts sequence
data, criteria for probe design, tags and primer sequences
through a graphical user interface. After the data are vali-
dated and carefully checked, a summary view of the
design is displayed and confirmed by the user to actually
start a design process. The criteria that are put in by the
user and accepted by the program are length of homolo-
gous sites, middle base identity, and Tm. A length in the
range 40–60 is ideal for the length of homologous parts of
the probe. This will give an ideal Tm of 50–60°C. The
actual program runs in four stages on a PC and the results
are written as a document file.
Laboratory validation of software results
We used the PathogenMIPer software to design MIPs for
105 different types of human papilloma viruses (HPV).
These genomes differ only slightly at most of the regions.
Input constraints included a Tm of 60°C, length of 50 bp
and middle base G. Multiple probes were designed for
each target pathogen, and these probes complement dif-
ferent regions of the genome in order to exploit the varia-
bility of the whole genome and detect even small copies
of the pathogen in the sample. In a preliminary test,
twenty-four of the resulting probes (see Table 1) were
used in a MIP assay designed for very sensitive detection
of multiple pathogens in a sample. These 24 probes were
selected in such a way, representing the 24 most commonBMC Bioinformatics 2006, 7:500 http://www.biomedcentral.com/1471-2105/7/500
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HPV genotypes, associated with human infections ranging
from genital and oral warts to cervical, and oral carcino-
mas, as reported in several clinical studies. The clinical
samples, containing extracted total genomic DNA from
cervical tumor scrapes, were obtained from Oncomatrix
[25].
Using these samples as well as purified HPV plasmids and
probes designed by PathogenMIPer, we performed an ini-
tial validation in the lab to evaluate specificity and sensi-
tivity using both MIP assay [6] and pyrosequencing [2]
results as a comparator.
The samples were subjected to PCR using GP5/GP6+
primers, followed by pyrosequencing [2]. The methods
for conducting the MIP assays are as described previously
[6] with the minor modifications. In brief, for the initial
annealing reaction, 400 ng genomic DNA or ~1–100 pg
HPV plasmids, ~5 fmol of each of the 24 probes, 0.05
units Ampligase (Epicentre, Madison, WI), and 0.5 units
Steps in the design of MIPs Figure 2
Steps in the design of MIPs: a) The software generates candidates for each target, based on the user specified criteria. b) 
The candidates are checked for their nonspecific binding with non targets and the host genome and nonspecific ones are elim-
inated and the specific ones are selected for designing MIP probes. n = genome length; k = user specified target binding length 
of probe; Kmer = genome fragment or oligo of length = k. (Numerical value of K = k).
(step 9)
Collection of target data
select next Kmer
Select next target
n - k + 1 Kmers generated for target
Kmer has
close match in
non-target?
Add the Kmer as candidate
Last
target?
Candidates
Go to Step B
END
START STEP B START
Select next  candidate
Select next non-target
Select next target
The total
similarity >
75%?
Check with the host genome/background
Get the tags if any
to add to the probe
Construct the probe
Probes
END STEP B
NO
YES
YES
NO
NO
NO
YES
YES
(steps  1-3)
( steps 4-7 )
(step 8 )
(step 8 )
(step 9)
a) b)
The total
similarity >
75%?BMC Bioinformatics 2006, 7:500 http://www.biomedcentral.com/1471-2105/7/500
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Stoffel fragment DNA polymerase (Applied Biosystems,
Foster City, CA) in 10 µL of 20 mmol/L Tris-HCl (pH 8.3),
25 mmol/L KCl, 10 mmol/L MgCl2, 0.5 mmol/L NAD,
0.01% Triton X-100 and 0.5 mM dGTP were incubated for
4 minutes at 20°C, 5 minutes at 95°C and then 15 min-
utes at 60°C, the reaction was cycled 10 cycles. Subse-
quently, 10 units exonuclease I and 200 units exonuclease
III (Epicentre, Madison, WI) were added and the mixture
was incubated for 60 minutes at 37°C and 20 minutes at
80°. Following exonucleolysis, the reaction was subjected
to uracil depurination and cleavage with 2 units uracil-N-
glycosylase (New England Biolabs, Ipswich, MA) in 20 µL
of 1.6 mmol/L MgCl2, 10 mmol/L Tris-HCl (pH 8.3), and
50 mmol/L KCl and incubated for 60 minutes at 37°C
and 20 minutes at 80°C. To amplify the inverted probes,
1.5 units AmpliTaq Gold (Applied Biosystems), 10 pmol
of each universal primer in 25 µL of 1.6 mmol/L MgCl2,
10 mmol/L Tris-HCl (pH 8.3), 50 mmol/L KCl, and 112
µmol/L deoxynucleotide triphosphate (dNTP) were
added to the genotyping reactions.
The reactions were amplified in 35 cycles of 95°C for 30
seconds, 55°C for 30 seconds, and 72°C for 10 seconds.
Microarray preparation
Microarrays were prepared using CodeLink activated
slides (Amersham, Piscataway, NJ) with 5'amine-modi-
fied oligonucleotide. Oligonucleotides were printed onto
microarray slides from a solution containing 1× printing
buffer (50 mM sodium phosphate, pH 8.5), 20 µM probe
using a microarrayer (BioDot, Inc., Irvine, CA). Positive
and negative controls were printed on the microarray as
well.
Each sample was printed in 4 replicates and 2 arrays were
present on each chip. The post-printing processing of the
microarray-chips were performed as recommended by the
slide manufacturer.
Microarray hybridization
For the target hybridization step we used 50 µL of bioti-
nylated PCR products, 1× hybridization buffer (100 mM
MES, 1 M [Na+], 20 mM EDTA, 0.01 Tween 20) and 1.25×
Denhardt's solution. The hybridization was performed at
42°C for 12–16 h. After hybridization, the microarray was
washed with wash buffer (6× SSPE, 0.1% Tween 20) 2
times at 50°C for 2 min and once at room temperature for
2 min. The microarray was labeled for 10 min at 50°C
with a solution containing streptavidin-allophycocyanin
conjugated (1 mg/ml), 6× SSPE, 1× Denhardt's solution
and 0.01% Tween 20. Following washing, 3 times in wash
buffer, the microarray was assayed for fluorescent inten-
sity at 635 nm using a GenePix 4000 fluorescent scanner
(Axon Instrument, Foster City, CA) set to scan at 450 PMT.
We used GenePix Pro software to determine the total flu-
orescent signal from each feature. To further confirm the
results, 10 µl of the same PCR product that was used in
microarray hybridization was sequenced by pyrosequenc-
ing as described by Gharizadeh et al [2].
The sensitivity (Sn) and specificity (Sp) of any system can
be defined in terms of four outcomes – true positive (TP),
true negatives (TN), false positives (FP), false negatives
(FN) [17,18]. In our assay, the sensitivity is the fraction of
actual positives which are predicted as positives, and spe-
cificity is the overall fraction of prediction that is correct.
This correctness was checked by pyrosequencing method
[2].
Results
Unique sequence generation
As described above, candidate homologous sequences
were checked and evaluated, and the bad ones were elim-
inated (steps 1–6). Then, the average melting temperature
of the candidates was calculated to check whether it was
feasible to design MIPs with the specified Tm. Next, all
candidates were checked for the middle base, and then for
their Tm. The software designed total 4244 candidates for
105 HPV types, for a user specified Tm of 60°C (the soft-
ware used 60 ± 4°C), length 50 bp and middle base G. On
an average 40 candidates were generated for each of the
105 HPV type genomes. The number of candidates gener-
Table 1: The HPV plasmid types tested in the laboratory with 
MIPs designed with the PathogenMIPer software.
Types of HPV plasmids tested Accession number
HPV 6 X00203
HPV 11 M14119
HPV 16 K02718
HPV 18 X05015
HPV 31 J04353
HPV 33 M12732
HPV 34 X74476
HPV 35 M74117
HPV 39 M38185
HPV 40 X74478
HPV 42 M73236
HPV 43 NC_005349
HPV 44 U31788
HPV 45 X74479
HPV 51 M62877
HPV 52 X74481
HPV 56 X74483
HPV 58 D90400
HPV 59 X77858
HPV 66 U31794
HPV 68 NC_004710
HPV 69 M73258
HPV 73 U21941
HPV 82 X94165BMC Bioinformatics 2006, 7:500 http://www.biomedcentral.com/1471-2105/7/500
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ated for each genome varied from 30 to 75 depending on
their genomic variability.
Candidate selection
As described above, in steps 4–6, the candidates for each
HPV genotype target were checked against non-target
genomes for their similarity. We checked the candidates of
each HPV type against the genomes of other HPV types for
similarity. The two homologous sites of the probes were
evaluated in such a way that if they had any sequence
matches in a non-target genome in the middle region,
they incur much higher penalties than for the matches dis-
tal to the middle region. For each of the comparisons of
the homologous sites of the probe against a non-target-
genome, the total penalty score is checked against a
threshold cut off value, set by the software based on the
minimum mismatch percent specified by the user while
setting up parameters for the design of MIPs. If the score
exceeded the cutoff, the candidate was eliminated. When
this filter was used against the candidate HPV probes gen-
erated in the previous step, PathogenMIPer returned a
total of 2245 candidates, or 52% of the original candi-
dates. The remaining 48% of the candidates were dis-
carded in this step due to potential non-specific binding
with non-target-genomes. The number of candidates
returned per genome varied from 3 to 41 at the end of fil-
tering.
Screen against the host genome
Finally (Steps 7–9), the best candidates were checked
against the potential background or host genome through
a remote BLAST and genome database on the NCBI server.
Non-specific binding was reduced by making sure that the
target-specific probe would not have more than 80%
matches to the non-target genomes, or in their potential
host genome. For the probes developed against 105 HPV
types, the filtered candidates were subjected to BLAST
against the human genome (the potential host), and
PathogenMIPer eliminated 61 candidate sequences based
on the matches in host genome, rendering more specifi-
city for the assay. The software returned 2184 candidate
probes for all the 105 types of HPV.
Tag placement
Once the homologous site construction is completed, the
user can add predefined tag sequences to the homologous
constructs. These tag sequences can be universal primers
for the amplification of the binding signal, and/or molec-
ular barcodes for the detection of the targets using tagAr-
ray (Affymetrix, Santa Clara, CA) or by sequencing
methods such as pyrosequencing [2].
The tag sequences input by the user are added in the pre-
ferred order as shown in the figure 1. Figure 1 shows a
well-constructed standard MIP consisting of six parts: two
homologous constructs, two universal primers (one for-
ward and one reverse), a restriction enzyme binding site
and a molecular bar code sequence. These parts have to be
constructed in a specific order in order for the MIP to work
perfectly. This is done by the PathogenMIPer software
interactively. The tags when added to the probe sequence
may generate sequences complementary to probes of
other targets included in the assay, resulting in cross
hybridizations and oligo-dimer formations, which will
render the results to be false positive. The PathogenMIPer
software checks all the constructed probes, and eliminates
the ones having problems in tags. The final selected
probes are written in a file, saving the eliminated ones in
a separate file. The user can look at the eliminated ones
and can change the tags in those eliminated ones and later
choose to include them in the assay. The user can follow
and add individual steps or finish the design process in a
single step.
Laboratory validation
The MIP assay was performed in 7 steps as depicted in
figure1(A–E). The PathogenMIPer probes detected all 24
HPV types (100% sensitivity) when tested on plasmids
with no false positives (100% specificity). In more com-
plex clinical samples, the PathogenMIPer probes were
able to produce distinct signals for the detection of single
as well as multiple infections. Also, all 24 HPV types were
detected in clinical samples (100% sensitivity as com-
pared to conventional genotyping results) with no false
positives (as compared to conventional genotyping tech-
niques such as pyrosequencing). The data are shown in
Table 2, 3. The pyrogram data for each of the samples were
on par with the results of MIP assay.
Performance
Software performance of probe design is mainly limited
by the amount of available memory, and the processor
speed. The initial phase of generating candidate homolo-
gous sites (Steps 1–4) takes considerable processing time.
In the example described here, this stage took ~3 hours. If
more constraints are applied, the processing time will be
increased, as more and more testing processes are done on
the probe candidates. The number of targets and the
length of each target affects the processing time as well.
The total processing time is also depending on the
number of candidates returned in the first step. When the
number of targets increases, the processing time increases
exponentially. Another major factor for the processing
time is the divergence of the pathogen genomes. When
the genomes of pathogens included in a MIP assay are
more divergent, or distant, a greater number of candidates
are generated and the processing time is longer.
The second phase of evaluating the candidates (Steps 5–
7), is a very computationally intensive process, and theBMC Bioinformatics 2006, 7:500 http://www.biomedcentral.com/1471-2105/7/500
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time taken for this step (~50 minutes in our case) also
depends on the parameters specified by user. The last step,
in which the sequences are checked against the host
genome through a BLAST, was done on the genome data-
base at NCBI server. The criteria for BLAST are set by the
PathogenMIPer software and the BLAST software called
upon is the current version running remotely on the NCBI
server.  Although this takes additional processing time
(~9.5 hours in this example), it adds to the quality of the
MIP assay by increasing uniqueness and reducing noise.
When used for designing 105 different types of human
papilloma viruses, PathogenMIPer generated a complete
pool of probe sequences in less than 15 hours. The soft-
ware is quite flexible in allowing candidates generated in
each of the steps to be viewed, checked and accessed for
editing so that one can go back to any step in the process
and revise the design without deleting the candidates of
the previous design, although such interventions would of
course be more time-consuming.
Discussion
In preliminary tests with just 24 probes against 24 HPV
genotypes, (i.e. one probe for each genotype present), we
were able to sensitively detect all 24, with a lower limit of
detection for purified plasmid as low as ~1 pg. In addi-
tion, we were able to detect multiple infections in samples
containing HPV plasmids, without false positives, result-
ing in a specificity of 100%. Note that although Pathogen-
MIPer designed 3 – 20 probes for each HPV type, this
initial validation used only one probe per genotype. By
relying on a single probe for the entire genome of HPV,
which is ~8000 bp long, poor binding or even non-bind-
ing of the probe to the target would result, if mutations
occur in the same locus chosen for the design of the MIP
for these genotypes, leading to suboptimal results. A more
complete diagnostic would necessarily anticipate such a
problem by incorporating multiple probes for those sub-
types whose genetic variation makes their identity more
difficult to distinguish.
The PathogenMIPer system is extendable, with the addi-
tion of new modules and new design strategies. Because
the quality requirements and other criteria for probes vary
for different MIP assays, this software is able to support
the design of different types of oligonucleotides, based on
the constraints specified by the user. Although the
processing time initially increases exponentially with the
number of target genomes, this processing time levels off
after a certain number of targets/genomes, as the software
designs candidates by progressive elimination of non-spe-
cific candidates.
Although the PathogenMIPer software is a tool for the
design of highly specific oligonucleotides for use in MIP
assays, this system essentially serves as an in silico multiplex
test system, whereby one can check the feasibility of design-
ing a MIP assay for the specific targets one might want to
include in a multiple detection technique. In the process
of identifying unique specific sequences and adding tag
sequences, universal primers, or cleavage sites to the com-
plete probe design for a MIP assay, PathogenMIPer per-
forms an efficient search for probes that have the highest
probable success of producing a viable and robust MIP
assay.
Conclusions
PathogenMIPer is a software for designing molecular
inversion probes for detection of multiple target DNAs in
a sample. This software simplifies development of MIP
assays, enabling broader use of MIP technology in the
detection through genotyping of pathogens that are com-
plex, difficult-to-amplify, or present in multiple subtypes.
PathogenMIPer facilitates large scale multiplex assays,
without the need for PCR sample preparation before anal-
ysis. For multiple detection strategies where amplification
Table 3: Summary of results.
TP TN FP FN Sn Sp
24 0 0 0 24/24 (100%) 20/20 (100%)
The sensitivity (Sn) and specificity (Sp) of any system can be defined in 
terms of four outcomes – true positive (TP), true negatives (TN), 
false positives (FP), false negatives (FN) [17, 18]. In our assay, the 
sensitivity is the fraction of actual positives which are predicted as 
positives, and specificity is the overall fraction of prediction that is 
correct. When the MIPs designed using PathogenMIPer were used in 
detection, it gave a sensitivity of 100% and a specificity of 100%.
Table 2: The results of clinical samples tested with the HPV MIPs 
designed with PathogenMIPer.
Sample # Results from MIP assay Results from conventional genotyping
1) OM-1078 HPV-16 HPV-16
2) OM-1272 HPV-16 HPV-16
3) OM-1299 Negative Negative
4) OM-1301 HPV-16 HPV-16
5) OM-1452 HPV-18 HPV-18
6) OM-1464 HPV-16 HPV-16
7) OM-1530 HPV-16 HPV-16
8) OM-1569 HPV-59 HPV-59
9) OM-1668 HPV-59 HPV-59
10) OM-1741 HPV-18 HPV-18
11) OM-1751 HPV-16 HPV-16
12) OM-1848 HPV-45 HPV-45
13) OM-1854 HPV-18 HPV-18
14) OM-1967 HPV-16 HPV-16
15) OM-1980 HPV-18 HPV-18
16) OM-2006 HPV-16 HPV-16
17) OM-2059 HPV-16 HPV-16
18) OM-2215 HPV-18 HPV-18
19) OM-2257 HPV-16 HPV-16
20) OM-2258 HPV-45 HPV-45BMC Bioinformatics 2006, 7:500 http://www.biomedcentral.com/1471-2105/7/500
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by a common primer is not possible, the feasibility of
developing a MIP assay can be interrogated through our in
silico system prior to launching costly and time-consum-
ing laboratory experiments. The system can be extended
to design probes for new types of assays such as hairpin
inversion probes. Extending the software by adding vari-
ous modules for designing different types of primers and
probes is under way.
Availability and requirements
PathogenMIPer software is available as an additional file
with the article.
(See Additional files 1, 2, 3, 4, and 5).
Name: PathogenMIPer
OS: Windows
Language: Perl
Requirements: Internet connection for background check-
ing.
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